InvestorsHub Logo
Followers 30
Posts 4277
Boards Moderated 0
Alias Born 03/20/2011

Re: Solarfuture post# 41

Sunday, 09/11/2022 9:07:47 PM

Sunday, September 11, 2022 9:07:47 PM

Post# of 154
It's nice exposure at ESMO 2022 there is no doubt about that.

Details on IMA402 have been published before in their June 22 Corporate update presentation here:

https://investors.immatics.com/static-files/3b9b921d-f109-447a-89cd-ab73db220caa

Starting at page 40 is where they discuss IMA402

IMA401 is targetting Mage and is in collaboration with BMS (checkpoint inhibitor - likely a CAR-T) - starting at page 37.
Not sure where clinical trials are at with IMA401.

Overall, imo, there is evidence appearing that TCR-T will be superior to CAR-T both in efficacy and reduced side effects/toxicities. Both are huge advances in medicine and potential game changers, imo

Multiple reasons here for IMTX to continue the uptrend.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IMTX News